Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
|Articles|March 9, 2010
- December 2009
- Volume 0
The Effect of New Treatments on Cancer-related Bone Loss
Author(s)Onclive Team
Advertisement
Articles in this issue
over 16 years ago
Amgen Honored for Best Pipeline & Best New Drugover 16 years ago
Do Insurers Spend Too Much on Administration and Too Little on Care?over 16 years ago
Exercise Maintains Function, Improves QoL for Patients With Lymphomaover 16 years ago
Continuing Education Opportunities on the Webover 16 years ago
News Briefs & FDA Updatesover 16 years ago
News & Opinionover 16 years ago
Decline in Cancer Deaths No Reason to Get ComplacentAdvertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5